Alzheimer's Drug Discovery Foundation and Association for Frontotemporal Dementias Announce Request for Proposals
The Alzheimer's Drug Discovery Foundation and the Association for Frontotemporal Dementias seek to accelerate and support drug discovery for FTD and related dementias through the Frontotemporal Dementia Drug Discovery Program Request for Proposals.
Research investigating the pathologic mechanisms of neurodegeneration in frontotemporal dementia and related disorders has advanced recently, creating new potential targets for drug discovery. Examples of programs appropriate for this RFP include, but are not limited to, target validation studies, development and testing of novel high throughput screening assays, medicinal chemistry on lead compounds, identification and in vitro testing of potentially disease-modifying lead compounds, testing of lead compounds in a relevant animal model for preclinical proof of concept, development and testing of targeted gene delivery strategies, development of biomarkers to accelerate drug development and early diagnosis, and innovative pilot clinical trials. Funding will not support applications for basic research.
ADDF/AFTD will provide individual grants for one year with the possibility of follow-up funding. Applications may be submitted by nonprofit academic institutions and for-profit biotechnology companies, both public and private, worldwide. Collaborative teams of neuroscientists and researchers in drug discovery disciplines such as medicinal chemistry and drug delivery are also encouraged to apply.
